Payment overview · 2025
General Payments
$627.64
38 reported records · 11 companies
Healthcare provider profile · identity verified
Chris-Gerald Ferguson
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANGELO, TX · NPI 1760813547
Verified facts
What the public records show
CMS Open Payments records show Chris-Gerald Ferguson received $627.64 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.76 | 28.3% | 15 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $156.93 | 25.0% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.05 | 10.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.06 | 6.4% | 2 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $39.11 | 6.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.29 | 5.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.91 | 4.6% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $26.79 | 4.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.64 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.23 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.87 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $627.64 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $132.38 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $132.38 | 11 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $103.02 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $67.05 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $65.23 | 3 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $45.99 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.38 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.29 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $7.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 106 |
| Gabapentin | Gabapentin | 358 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 88 |
| Lisinopril | Lisinopril | 255 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 61 |
| Furosemide | Furosemide | 186 | 55 |
| Metformin Hcl | Metformin Hcl | 180 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 56 |
| Tramadol Hcl | Tramadol Hcl | 174 | 32 |
| Losartan Potassium | Losartan Potassium | 168 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 23 |
| Montelukast Sodium | Montelukast Sodium | 146 | 45 |
| Omeprazole | Omeprazole | 139 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 39 |
| Meloxicam | Meloxicam | 136 | 34 |
| Simvastatin | Simvastatin | 128 | 34 |
| Trazodone Hcl | Trazodone Hcl | 116 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 26 |
| Sertraline Hcl | Sertraline Hcl | 106 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 105 | 15 |
| Carvedilol | Carvedilol | 101 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 26 |
| Allopurinol | Allopurinol | 94 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 19 |
| Potassium Chloride | Potassium Chloride | 92 | 33 |
| Alprazolam | Alprazolam | 88 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 21 |
| Glipizide | Glipizide | 78 | 20 |
| Famotidine | Famotidine | 71 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 18 |
| Glipizide Er | Glipizide | 68 | 18 |
| Ozempic | Semaglutide | 67 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 13 |
| Mirtazapine | Mirtazapine | 59 | 12 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 11 |
| Linzess | Linaclotide | 54 | 11 |
| Eliquis | Apixaban | 53 | 16 |
| Carisoprodol | Carisoprodol | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 19 |
| Finasteride | Finasteride | 47 | 11 |
| Alendronate Sodium | Alendronate Sodium | 46 | 15 |
| Ezetimibe | Ezetimibe | 46 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Atenolol | Atenolol | 37 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Acarbose | Acarbose | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $627.64 · 38 records | Novo Nordisk Inc | ABRYSVO, Auvelity, CABENUVA, CAPVAXIVE, COMIRNATY, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, Kimyrsa, MOUNJARO, Ozempic, PIFELTRO, PREVNAR 20, PROLIA, Rezzayo, Rybelsus, SHINGRIX, Wegovy, ZEPBOUND, ZERBAXA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error